The estimated Net Worth of Mark A Glickman is at least $637 Tysiąc dollars as of 6 December 2022. Mr. Glickman owns over 1,734 units of Esperion Therapeutics stock worth over $3,017 and over the last 9 years he sold ESPR stock worth over $9,733. In addition, he makes $624,392 as Chief Commercial Officer at Esperion Therapeutics.
Mark has made over 3 trades of the Esperion Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,734 units of ESPR stock worth $3,017 on 6 December 2022.
The largest trade he's ever made was buying 25,000 units of Esperion Therapeutics stock on 16 May 2016 worth over $92,000. On average, Mark trades about 2,951 units every 218 days since 2016. As of 6 December 2022 he still owns at least 1,734 units of Esperion Therapeutics stock.
You can see the complete history of Mr. Glickman stock trades at the bottom of the page.
Mark A. Glickman serves as Chief Commercial Officer of the Company. He has served as our Chief Commercial Officer since April 2018. Prior to joining Esperion, Mr. Glickman served as the Chief Commercial Officer at Aralez Pharmaceuticals Inc. from June 2016 to March 2018 where he led the commercial activities for the company. From June 2015 to February 2016, Mr. Glickman was the Chief Commercial Officer of POZEN Inc., which was combined with Tribute Pharmaceuticals Canada Inc. to form Aralez Pharmaceuticals. Mr. Glickman previously served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals, a specialty biopharmaceutical company, from February 2012 to March 2015. From February 2009 to February 2012, he served as Vice President in the medical device division at Otsuka America Pharmaceutical, Inc., a pharmaceutical and medical device company and a subsidiary of Otsuka America, Inc. Prior to Otsuka, Mr. Glickman served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., a commercial-stage pharmaceutical company, from September 2007 to September 2009. Before joining Oscient, from May 2007 to September 2007, Mr. Glickman served as Vice President of Sales at Bayer Healthcare's Diabetes Care Division. From 2001 to 2007, he held various positions at Kos Pharmaceuticals, including Director of Marketing, Regional Sales Director and Vice President of Sales. Mr. Glickman started his pharmaceutical career at Bristol-Myers Squibb where he was responsible for the marketing of cardiovascular products, including the blockbuster Plavix. Mr. Glickman holds a Master of Business Administration degree from New York University.
As the Chief Commercial Officer of Esperion Therapeutics, the total compensation of Mark Glickman at Esperion Therapeutics is $624,392. There are 1 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of $1,080,850.
Mark Glickman is 54, he's been the Chief Commercial Officer of Esperion Therapeutics since 2018. There are 7 older and 7 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE, MA, 02138.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... oraz Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: